Gerald Higgins

Background

About Gerald Higgins

Throughout a distinguished career spanning foundational neuroscience, federal leadership, and translational innovation, this researcher has made sustained contributions across multiple domains of biomedical science. As co-author, alongside John Hardy, of the seminal amyloid cascade hypothesis published in Science — one of the most cited conceptual frameworks in modern Alzheimer's research — he helped shape the foundational understanding of Alzheimer's disease pathogenesis. During his postdoctoral tenure at the Scripps Research Institute in the 1980s, he achieved the first cloning and human brain mapping of three critical genes: APP (amyloid precursor protein), SNAP-25 (synaptosomal associated protein 25), and MAG (myelin associated glycoprotein), work recognized on the cover of Science (Volume 283). His early investigations into neuronal plasticity, conducted in collaboration with Dr. Fred (Rusty) Gage — now at the Salk Institute — produced multiple publications advancing the understanding of spatial learning and neural adaptation in the brain. His leadership contributions have spanned some of the nation's most influential institutions, including the National Institute on Aging, the Defense Advanced Research Projects Agency, and the National Library of Medicine, where he co-directed the Computer-Aided Surgery seminar series. A pioneer in the application of machine learning to medicine, he was instrumental in the development of AutoCyte®, the first FDA-reviewed microscopic imaging system to employ early convolutional neural networks for the discrimination of tumor from normal cells in Pap smears — a milestone achieved as early as 1994. He co-founded and scaled a simulation-based medical training company that secured more than $20 million in funding before being successfully acquired by Laerdal Medical Corporation. Within the MedStar Health network, he served in an executive innovation leadership capacity and co-developed with Dr. Mark Smith the Axzzyi electronic health record, subsequently acquired by Microsoft Health Solutions. He also provided direct leadership in the development and commercialization of GeneSight®, the first successful pharmacogenomic diagnostic test — administered to more than five million patients — before its acquisition by Myriad Genetics. Across his career, he has overseen nearly $50 million in sponsored translational research, reflecting a sustained commitment to bridging scientific discovery and clinical application.